ASX - By Stock
|
NOX |
Re:
BMS NOX to partner on pilot study
|
|
vrs37
|
7 |
2.4K |
3 |
26/11/20 |
26/11/20 |
ASX - By Stock
|
7
|
2.4K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
BMS NOX to partner on pilot study
|
|
vrs37
|
7 |
2.4K |
2 |
26/11/20 |
26/11/20 |
ASX - By Stock
|
7
|
2.4K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil receives Swiss regulatory approval
|
|
vrs37
|
61 |
27K |
2 |
14/11/20 |
14/11/20 |
ASX - By Stock
|
61
|
27K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil receives Swiss regulatory approval
|
|
vrs37
|
61 |
27K |
3 |
06/11/20 |
06/11/20 |
ASX - By Stock
|
61
|
27K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Bell Potter Report (inc SP valuation)
|
|
vrs37
|
15 |
9.9K |
2 |
30/10/20 |
30/10/20 |
ASX - By Stock
|
15
|
9.9K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Bell Potter Report (inc SP valuation)
|
|
vrs37
|
15 |
9.9K |
2 |
30/10/20 |
30/10/20 |
ASX - By Stock
|
15
|
9.9K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Public Funding of Oncosil in Australia
|
|
vrs37
|
8 |
3.6K |
0 |
29/10/20 |
29/10/20 |
ASX - By Stock
|
8
|
3.6K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil achieves first commercial sale
|
|
vrs37
|
42 |
14K |
5 |
23/10/20 |
23/10/20 |
ASX - By Stock
|
42
|
14K
|
5
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil achieves first commercial sale
|
|
vrs37
|
42 |
14K |
0 |
22/10/20 |
22/10/20 |
ASX - By Stock
|
42
|
14K
|
0
|
|
ASX - By Stock
|
OSL |
Re:
Ann: OncoSil achieves first commercial sale
|
|
vrs37
|
42 |
14K |
1 |
22/10/20 |
22/10/20 |
ASX - By Stock
|
42
|
14K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Appendix 4C - quarterly
|
|
vrs37
|
12 |
3.3K |
1 |
21/10/20 |
21/10/20 |
ASX - By Stock
|
12
|
3.3K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Positive PanCO trial update on resected cohort
|
|
vrs37
|
7 |
2.5K |
4 |
20/10/20 |
20/10/20 |
ASX - By Stock
|
7
|
2.5K
|
4
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Positive PanCO trial update on resected cohort
|
|
vrs37
|
7 |
2.5K |
5 |
20/10/20 |
20/10/20 |
ASX - By Stock
|
7
|
2.5K
|
5
|
|
ASX - By Stock
|
OSL |
Re:
Ann: 2020 AGM CEO Presentation
|
|
vrs37
|
7 |
3.2K |
2 |
20/10/20 |
20/10/20 |
ASX - By Stock
|
7
|
3.2K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Positive PanCO trial update on resected cohort
|
|
vrs37
|
7 |
2.5K |
2 |
20/10/20 |
20/10/20 |
ASX - By Stock
|
7
|
2.5K
|
2
|
|
ASX - By Stock
|
BIT |
Re:
Ann: BIT225 HIV-1 Immunomodulatory Paper Published
|
|
vrs37
|
46 |
18K |
3 |
18/10/20 |
18/10/20 |
ASX - By Stock
|
46
|
18K
|
3
|
|
ASX - By Stock
|
BIT |
Re:
Ann: BIT225 HIV-1 Immunomodulatory Paper Published
|
|
vrs37
|
46 |
18K |
2 |
18/10/20 |
18/10/20 |
ASX - By Stock
|
46
|
18K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
OSL Chart
|
|
vrs37
|
114 |
78K |
4 |
06/10/20 |
06/10/20 |
ASX - By Stock
|
114
|
78K
|
4
|
|
ASX - By Stock
|
OSL |
Re:
OSL Chart
|
|
vrs37
|
114 |
78K |
1 |
06/10/20 |
06/10/20 |
ASX - By Stock
|
114
|
78K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
NOXCOVID-1 design
|
|
vrs37
|
5 |
2.2K |
2 |
05/10/20 |
05/10/20 |
ASX - By Stock
|
5
|
2.2K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
NOXCOVID-1 design
|
|
vrs37
|
5 |
2.2K |
3 |
05/10/20 |
05/10/20 |
ASX - By Stock
|
5
|
2.2K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Oct 2
|
|
vrs37
|
49 |
16K |
2 |
04/10/20 |
04/10/20 |
ASX - By Stock
|
49
|
16K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
OSL Chart
|
|
vrs37
|
114 |
78K |
3 |
04/10/20 |
04/10/20 |
ASX - By Stock
|
114
|
78K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
What do we know?
|
|
vrs37
|
5 |
1.9K |
5 |
03/10/20 |
03/10/20 |
ASX - By Stock
|
5
|
1.9K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
What do we know?
|
|
vrs37
|
5 |
1.9K |
3 |
03/10/20 |
03/10/20 |
ASX - By Stock
|
5
|
1.9K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
OSL Chart
|
|
vrs37
|
114 |
78K |
0 |
02/10/20 |
02/10/20 |
ASX - By Stock
|
114
|
78K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
|
|
vrs37
|
627 |
264K |
9 |
26/09/20 |
26/09/20 |
ASX - By Stock
|
627
|
264K
|
9
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Investor Update
|
|
vrs37
|
95 |
39K |
3 |
25/09/20 |
25/09/20 |
ASX - By Stock
|
95
|
39K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Investor Update
|
|
vrs37
|
95 |
39K |
1 |
24/09/20 |
24/09/20 |
ASX - By Stock
|
95
|
39K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Buy Signal
|
|
vrs37
|
36 |
15K |
2 |
22/09/20 |
22/09/20 |
ASX - By Stock
|
36
|
15K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Buy Signal
|
|
vrs37
|
36 |
15K |
0 |
22/09/20 |
22/09/20 |
ASX - By Stock
|
36
|
15K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
Protocol
|
|
vrs37
|
3 |
2.2K |
2 |
21/09/20 |
21/09/20 |
ASX - By Stock
|
3
|
2.2K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Protocol
|
|
vrs37
|
3 |
2.2K |
2 |
21/09/20 |
21/09/20 |
ASX - By Stock
|
3
|
2.2K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Noxopharm's NOXCOVID-1 trial BLOG
|
|
vrs37
|
4 |
2.2K |
2 |
12/09/20 |
12/09/20 |
ASX - By Stock
|
4
|
2.2K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Investor Update
|
|
vrs37
|
95 |
39K |
2 |
12/09/20 |
12/09/20 |
ASX - By Stock
|
95
|
39K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Investor Update
|
|
vrs37
|
95 |
39K |
0 |
11/09/20 |
11/09/20 |
ASX - By Stock
|
95
|
39K
|
0
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda COVID-19 Study Approved For Immediate Start
|
|
vrs37
|
6 |
2.5K |
2 |
11/09/20 |
11/09/20 |
ASX - By Stock
|
6
|
2.5K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
NOXCOVID
|
|
vrs37
|
8 |
2.7K |
2 |
08/09/20 |
08/09/20 |
ASX - By Stock
|
8
|
2.7K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
NOXCOVID
|
|
vrs37
|
8 |
2.7K |
3 |
08/09/20 |
08/09/20 |
ASX - By Stock
|
8
|
2.7K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
NOXCOVID
|
|
vrs37
|
8 |
2.7K |
4 |
08/09/20 |
08/09/20 |
ASX - By Stock
|
8
|
2.7K
|
4
|
|
ASX - By Stock
|
BIT |
Re:
Ann: Biotron Compounds Show Activity Against SARS-CoV-2 Virus
|
|
vrs37
|
440 |
143K |
3 |
08/09/20 |
08/09/20 |
ASX - By Stock
|
440
|
143K
|
3
|
|
ASX - By Stock
|
BIT |
Re:
Ann: Biotron Compounds Show Activity Against SARS-CoV-2 Virus
|
|
vrs37
|
440 |
143K |
6 |
08/09/20 |
08/09/20 |
ASX - By Stock
|
440
|
143K
|
6
|
|
ASX - By Stock
|
BIT |
Re:
Ann: Biotron Compounds Show Activity Against SARS-CoV-2 Virus
|
|
vrs37
|
440 |
143K |
3 |
07/09/20 |
07/09/20 |
ASX - By Stock
|
440
|
143K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Investor Update
|
|
vrs37
|
95 |
39K |
2 |
07/09/20 |
07/09/20 |
ASX - By Stock
|
95
|
39K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Investor Update
|
|
vrs37
|
95 |
39K |
2 |
07/09/20 |
07/09/20 |
ASX - By Stock
|
95
|
39K
|
2
|
|
ASX - By Stock
|
BIT |
Re:
Ann: Biotron Compounds Show Activity Against SARS-CoV-2 Virus
|
|
vrs37
|
440 |
143K |
1 |
07/09/20 |
07/09/20 |
ASX - By Stock
|
440
|
143K
|
1
|
|
ASX - By Stock
|
BIT |
Re:
Ann: Biotron Compounds Show Activity Against SARS-CoV-2 Virus
|
|
vrs37
|
440 |
143K |
3 |
07/09/20 |
07/09/20 |
ASX - By Stock
|
440
|
143K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Investor Update
|
|
vrs37
|
95 |
39K |
3 |
07/09/20 |
07/09/20 |
ASX - By Stock
|
95
|
39K
|
3
|
|
ASX - By Stock
|
BIT |
Re:
Ann: Biotron Compounds Show Activity Against SARS-CoV-2 Virus
|
|
vrs37
|
440 |
143K |
8 |
07/09/20 |
07/09/20 |
ASX - By Stock
|
440
|
143K
|
8
|
|
ASX - By Stock
|
BIT |
Re:
Ann: Biotron Compounds Show Activity Against SARS-CoV-2 Virus
|
|
vrs37
|
440 |
143K |
15 |
07/09/20 |
07/09/20 |
ASX - By Stock
|
440
|
143K
|
15
|
|